Parkinson Disease  >>  prasinezumab (RG7935)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
prasinezumab (RG7935) / Roche
NCT02095171: Single Ascending Dose Study of PRX002 in Healthy Subjects

Completed
1
40
US
PRX002, Placebo
Prothena Biosciences Limited, Hoffmann-La Roche
Parkinson's Disease
12/14
 
NCT02157714: Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Checkmark Multiple ascending dose study in Parkinson's disease
Jun 2018 - Jun 2018: Multiple ascending dose study in Parkinson's disease
Checkmark From P1b multiple ascending dose study [screenshot]
Feb 2018 - Feb 2018: From P1b multiple ascending dose study [screenshot]
Completed
1
64
US
PRX002, Placebo
Prothena Biosciences Limited, Hoffmann-La Roche
Parkinson's Disease
09/16
 

Download Options